Want to see JP:4934 full AI Analyst Report?
Premier Anti-Aging Co., Ltd. (4934) AI Stock Analysis
Premier Anti-Aging Co., Ltd.
(TSE/TYO:4934)
The overall score is constrained by a significant operational decline, with revenue and cash flow collapsing to minimal levels. The company's strong, low-debt balance sheet is the primary mitigating factor, providing a buffer against immediate solvency risk. Technicals show a short-term bounce but remain within a broader downtrend, while the P/E-based valuation lacks conviction given unstable earnings and no dividend support.
Premier Anti-Aging Co., Ltd. (4934) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.86B
- Dividend Yield
- ―
- Average Volume (3M)
- 8,288
- Price to Earnings (P/E)
- 13.2
- Beta (1Y)
- 0.66
- Revenue Growth
- -14.09%
- EPS Growth
- -22.72%
- Country
- Japan
- Employees
- 216
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model
Company Description
Premier Anti-Aging Co., Ltd. engages in the planning, development, import, export, mail order/EC, wholesale, and retail of cosmetics, health foods, and recovery wear in Japan. The company is involved in anti-aging and recovery businesses; and manufac...
How the Company Makes Money
Premier Anti-Aging Co., Ltd. generates revenue primarily by selling its anti-aging-related products and services. Key revenue streams are expected to include (1) product sales to consumers (e.g., via direct-to-consumer channels such as online sales)...
Premier Anti-Aging Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak, driven by a severe multi-year revenue decline and razor-thin profitability. The income statement (score 35) and cash flow (score 25) are deeply concerning, showing minimal earnings and poor cash conversion. The balance sheet (score 72) is a relative strength with low leverage, but it cannot offset the deteriorating operational trends.
Income Statement
35NegativeBalance Sheet
72PositiveCash Flow
25Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.88B | 13.88B | 16.16B | 20.36B | 26.40B | 33.91B |
| Gross Profit | 10.56B | 10.56B | 12.39B | 16.10B | 19.24B | 26.63B |
| EBITDA | 795.00M | 795.00M | 916.00M | 390.00M | -423.24M | 2.50B |
| Net Income | 364.00M | 364.00M | 471.00M | -1.48B | -733.97M | 1.42B |
Balance Sheet | ||||||
| Total Assets | 10.24B | 10.24B | 10.14B | 11.05B | 12.18B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 4.95B | 4.95B | 4.66B | 4.76B | 4.67B | 2.97B |
| Total Debt | 1.37B | 1.37B | 1.11B | 2.44B | 2.26B | 1.41B |
| Total Liabilities | 3.29B | 3.29B | 3.53B | 4.92B | 4.57B | 3.95B |
| Stockholders Equity | 6.96B | 6.96B | 6.61B | 6.12B | 7.61B | 8.35B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 131.00M | 1.44B | -204.00M | 2.40B | -3.35B |
| Operating Cash Flow | 0 | 217.00M | 1.47B | 425.00M | 2.42B | -3.32B |
| Investing Cash Flow | 0 | -227.00M | -229.00M | -540.00M | -900.97M | -297.68M |
| Financing Cash Flow | 0 | 267.00M | -1.34B | 183.00M | 179.77M | 501.62M |
Premier Anti-Aging Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Negative. The current price of 552.00 is below the 20-day moving average (MA) of 573.45, below the 50-day MA of 586.24, and below the 200-day MA of 631.93, indicating a bearish trend. The MACD of -7.83 indicates Positive momentum. The RSI at 31.05 is Neutral, neither overbought nor oversold. The STOCH value of 24.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4934.
Premier Anti-Aging Co., Ltd. Peers Comparison
Overall Rating
JP:493383Outperform
JP:492580Outperform
JP:491871Outperform
JP:492665Neutral
JP:493651Neutral- JP:493450Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4933 | 83Outperform | JPY 43.78B | 19.75 | ― | 0.89% | 13.71% | -16.12% |
| JP:4925 | 80Outperform | JPY 6.32B | 9.28 | ― | 2.39% | 0.16% | 6.35% |
| JP:4918 | 71Outperform | JPY 1.71B | 8.74 | ― | 5.03% | -6.17% | -55.84% |
| JP:4926 | 65Neutral | JPY 5.30B | 28.98 | ― | 1.61% | 3.17% | -27.27% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| JP:4936 | 51Neutral | JPY 7.04B | -14.07 | ― | 3.50% | -0.08% | -246.12% |
| JP:4934 | 50Neutral | JPY 4.86B | 13.22 | ― | ― | -14.09% | -22.72% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4934 | Premier Anti-Aging Co., Ltd. | 552.00 | -155.00 | -21.92% | |
| JP:4918 | Ivy Cosmetics Corporation | 298.00 | -20.81 | -6.53% | |
| JP:4925 | HABA Laboratories, Inc. | 1671.00 | 46.91 | 2.89% | |
| JP:4926 | C'BON COSMETICS Co., Ltd. | 1242.00 | 69.27 | 5.91% | |
| JP:4933 | I-ne CO., LTD. | 2483.00 | 1263.43 | 103.60% | |
| JP:4936 | AXXZIA, Inc. | 286.00 | -153.01 | -34.85% |
Premier Anti-Aging Co., Ltd. Corporate Events
Premier Anti-Aging Details Growth Plans and Earnings Outlook
Premier Anti-Aging Co., Ltd., a beauty and personal care company listed on the TSE Growth Market, operates in the anti-aging skincare segment with a focus on preventative and corrective products. It targets consumers in the expanding wellness and hig...
Premier Anti-Aging Beats Forecasts but Restructuring China Unit Weighs on Bottom Line
Premier Anti-Aging reported that net sales and profits for the fiscal year ended July 31, 2026 modestly exceeded its June forecast, with net sales reaching ¥13.88 billion and operating profit rising to ¥494 million, aided by strong performa...
Premier Anti-Aging Unveils FY2026 Results and FY2027 Outlook
Premier Anti-Aging Co., Ltd. has released its FY2026 results briefing materials, outlining company performance, segment status in anti-aging and recovery businesses, and sustainability initiatives. The company also presented its earnings forecast for...
Premier Anti-Aging Profits Slide as Sales Decline and Outlook Remains Cautious
Premier Anti-Aging reported a 14.1% decline in net sales to ¥13.88 billion for the year ended July 31, 2026, with operating profit down 19.8% to ¥494 million and profit attributable to owners of parent falling 22.8% to ¥364 million. De...
Premier Anti-Aging Restructures China Operations, Shuts Shanghai Subsidiary
Premier Anti-Aging Co., Ltd. has decided to dissolve and liquidate its consolidated subsidiary Premier Anti-Aging (Shanghai) Co., Ltd. as part of a structural reform of its China operations. The move reflects a strategic shift in how the company mana...
Premier Anti-Aging to Liquidate Loss-Making China Subsidiary and Pivot to Cross-Border E-Commerce
Premier Anti-Aging Co., Ltd. has resolved to dissolve and liquidate its wholly owned Chinese subsidiary, Premier Anti-Aging (Shanghai) Co., Ltd., as part of a structural reform of its operations in China. The Shanghai unit, established in 2021 to imp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 15, 2026